Recombinant, selective acting (ARTILYSIN®e) antimicrobial proteins engineered and developed by ISO 13485 certified Lisando GmbH to efficiently combat bacterial pathogens. The resulting ARTILYSIN® platform finds application in almost all fields that are under bacterial attack.
- is effective against gram positive bacteria (e.g. Staphylococcus, Streptococcus)
Core Technologies and Services
Based on the ARTILYSIN® platform, applicable ARTILYSIN® is developed according to customer specifications. ARTILYSIN® acts selectively so that pathogenic target bacteria are foremost eliminated and the microbiome remains intact. The bacteria are lysed via a mechanical, physical mechanism within seconds. ARTILYSIN® is environmentally-friendly, is rapidly biologically degraded and therefore dose not accumulate in the environment. ARTILYSIN® compared to antibiotics is significantly more stable to the development of resistance.
Patent, Licenses, Co-operations
Lisando GmbH distinguishes itself with goal-directed and expeditious work, is punctual and works closely with customers. Lisando GmbH has much experience in working with large concerns and medium-sized companies. The ARTILYSIN® platform is protected by a broad patent portfolio.
Please contact our office directly: Markus Matuschka v. Greiffenclau email@example.com